| Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4 (NCT05603936) | Universitätsklinikum Hamburg-Eppendorf | 2022-03-01 |
| A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia (NCT05246033) | Visen Pharmaceuticals (Shanghai) Co., Ltd. | 2022-01-05 |
| Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia (NCT05116046) | Pfizer | 2021-12-24 |
| Extension Study of Infigratinib in Children With Achondroplasia (ACH) (NCT05145010) | QED Therapeutics, a BridgeBio company | 2021-12-06 |
| Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy) (NCT05328050) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2021-09-01 |
| A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia (NCT04638153) | Pfizer | 2020-12-02 |
| A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia (NCT04554940) | BioMarin Pharmaceutical | 2020-10-10 |
| A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia (NCT04085523) | Ascendis Pharma A/S | 2020-06-24 |
| Study of Infigratinib in Children With Achondroplasia (NCT04265651) | QED Therapeutics, a BridgeBio company | 2020-03-10 |
| Radiological Analysis on Patients With Achondroplasia Disorder (NCT04184817) | Hospices Civils de Lyon | 2020-02-15 |
| Prospective Clinical Assessment Study in Children With Achondroplasia (ACH) (NCT04035811) | QED Therapeutics, a BridgeBio company | 2019-08-12 |
| A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia (NCT03875534) | Ascendis Pharma A/S | 2019-06-19 |
| An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia (NCT03989947) | BioMarin Pharmaceutical | 2019-06-12 |
| Lifetime Impact Study for Achondroplasia (NCT03872531) | BioMarin Pharmaceutical | 2019-03-31 |
| Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia. (NCT03794609) | Pfizer | 2018-06-15 |
| A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia (NCT03583697) | BioMarin Pharmaceutical | 2018-06-13 |
| Lifetime Impact of Achondroplasia Study in Europe-LIAISE (NCT03449368) | BioMarin Pharmaceutical | 2017-12-17 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia (NCT03424018) | BioMarin Pharmaceutical | 2017-12-12 |
| The Norwegian Adult Achondroplasia Study (NCT03780153) | Sunnaas Rehabilitation Hospital | 2017-03-01 |
| A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia (NCT03197766) | BioMarin Pharmaceutical | 2016-12-12 |
| Achondroplasia Natural History Multicenter Clinical Study (NCT02597881) | Johns Hopkins University | 2016-04-01 |
| A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) (NCT02724228) | BioMarin Pharmaceutical | 2016-01-26 |
| A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia (NCT02055157) | BioMarin Pharmaceutical | 2014-01-13 |
| A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin (NCT01435629) | Novo Nordisk A/S | 2012-11-22 |
| A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia (NCT01603095) | BioMarin Pharmaceutical | 2012-04-01 |
| A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers (NCT01590446) | BioMarin Pharmaceutical | 2012-02-01 |
| C-Type Natriuretic Peptide and Achondroplasia (NCT01541306) | Nemours Children's Clinic | 2012-02-01 |
| Special Survey for Long Term Application (NCT01516229) | Novo Nordisk A/S | 1997-05-01 |
| Issues Surrounding Prenatal Genetic Testing for Achondroplasia (NCT00001536) | National Human Genome Research Institute (NHGRI) | 1996-08-01 |